Targeting RAS-driven human cancer cells with antibodies to upregulated and essential cell-surface proteins

Cited by papers we hold 4

• Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials · 2023
  No notice
• Maximizing CRISPRi efficacy and accessibility with dual-sgRNA libraries and optimal effectors · 2022
  No notice
• Modular cytokine receptor-targeting chimeras for targeted degradation of cell surface and extracellular proteins · 2022
  No notice
• Structure-based development of new RAS-effector inhibitors from a combination of active and inactive RAS-binding compounds · 2019
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.